WEREWOLF THERAPEUTICS INC. - COMMON STOCK

Werewolf Therapeutics Announces Pipeline and Business Updates

18 Dec 2025 08:00:01 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Presents Data Expanding Its PREDATOR® Platform at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

07 Nov 2025 09:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

04 Nov 2025 07:00:01 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer

08 Oct 2025 08:00:01 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

03 Oct 2025 09:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in the Upcoming H.C. Wainwright 27th Annual Global Investment Conference

02 Sep 2025 08:00:02 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

14 Aug 2025 07:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit

09 Jul 2025 08:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in the BIO International Convention

12 Jun 2025 08:00:01 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference

29 May 2025 08:00:00 Источник Nasdaq GlobeNewswire

HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124

20 May 2025 16:01:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in Hanson Wade’s 6th Annual Cytokine-Based Drug Development Summit

13 May 2025 08:00:01 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

08 May 2025 07:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

05 May 2025 08:05:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Participate in Upcoming Investor Conferences

05 May 2025 08:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer

17 Apr 2025 08:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

31 Mar 2025 08:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

11 Mar 2025 07:00:00 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

04 Mar 2025 08:00:01 Источник Nasdaq GlobeNewswire

Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

24 Feb 2025 07:30:00 Источник Nasdaq GlobeNewswire